Clinical Trial Update: Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Novartis' ECI830 is being studied as a single agent or in combination in adults with advanced HR+/HER2- breast cancer and other advanced solid tumors in a Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ccne1-amplified Solid Tumors

Drugs mentioned

• ECI830

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING